Literature DB >> 20884874

Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans.

Lena Persson1, Guoqing Cao, Lars Ståhle, Beatrice G Sjöberg, Jason S Troutt, Robert J Konrad, Cecilia Gälman, Håkan Wallén, Mats Eriksson, Ingiäld Hafström, Suzanne Lind, Maria Dahlin, Per Amark, Bo Angelin, Mats Rudling.   

Abstract

OBJECTIVE: To gain insight into the function of proprotein convertase subtilisin kexin type 9 (PCSK9) in humans by establishing whether circulating levels are influenced by diurnal, dietary, and hormonal changes. METHODS AND
RESULTS: We monitored circulating PCSK9 in a set of dynamic human experiments and could show that serum PCSK9 levels display a diurnal rhythm that closely parallels that of cholesterol synthesis, measured as serum lathosterol. In contrast to these marked diurnal changes in cholesterol metabolism, serum low-density lipoprotein (LDL) cholesterol levels remained stable during the diurnal cycle. Depletion of liver cholesterol by treatment with the bile acid-binding resin, cholestyramine, abolished the diurnal rhythms of both PCSK9 and lathosterol. Fasting (>18 hours) strongly reduced circulating PCSK9 and lathosterol levels, whereas serum LDL levels remained unchanged. Growth hormone, known to be increased during fasting in humans, reduced circulating PCSK9 in parallel to LDL cholesterol levels.
CONCLUSIONS: Throughout the day, and in response to fasting and cholesterol depletion, circulating PCSK9 displays marked variation, presumably related to oscillations in hepatic cholesterol that modify its activity in parallel with cholesterol synthesis. In addition to this sterol-mediated regulation, additional effects on LDL receptors may be mediated by hormones directly influencing PCSK9.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20884874     DOI: 10.1161/ATVBAHA.110.214130

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  51 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day.

Authors:  Yan Q Chen; Jason S Troutt; Robert J Konrad
Journal:  Lipids       Date:  2014-05       Impact factor: 1.880

Review 3.  Lipid lowering with PCSK9 inhibitors.

Authors:  Razvan T Dadu; Christie M Ballantyne
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

4.  Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance.

Authors:  Jean-Philippe Drouin-Chartier; André J Tremblay; Jean-Charles Hogue; Valéry Lemelin; Benoît Lamarche; Patrick Couture
Journal:  J Lipid Res       Date:  2018-06-26       Impact factor: 5.922

Review 5.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

6.  Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.

Authors:  John S Chorba; Adri M Galvan; Kevan M Shokat
Journal:  J Biol Chem       Date:  2017-12-19       Impact factor: 5.157

7.  Docosahexaenoic Acid Attenuates Cardiovascular Risk Factors via a Decline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Plasma Levels.

Authors:  Celia Rodríguez-Pérez; Vanu Ramkumar Ramprasath; Shuaihua Pu; Ali Sabra; Rosa Quirantes-Piné; Antonio Segura-Carretero; Peter J H Jones
Journal:  Lipids       Date:  2015-11-30       Impact factor: 1.880

8.  Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol.

Authors:  Moumita Ghosh; Cecilia Gälman; Mats Rudling; Bo Angelin
Journal:  J Lipid Res       Date:  2014-12-22       Impact factor: 5.922

9.  In vivo evidence that furin from hepatocytes inactivates PCSK9.

Authors:  Rachid Essalmani; Delia Susan-Resiga; Ann Chamberland; Marianne Abifadel; John W Creemers; Catherine Boileau; Nabil G Seidah; Annik Prat
Journal:  J Biol Chem       Date:  2010-12-08       Impact factor: 5.157

Review 10.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.

Authors:  Nicola Ferri; Massimiliano Ruscica
Journal:  Endocrine       Date:  2016-04-01       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.